AngioDynamics - ANGO Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $13.25
  • Forecasted Upside: 114.75%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$6.17
▲ +0.03 (0.49%)

This chart shows the closing price for ANGO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New AngioDynamics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ANGO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ANGO

Analyst Price Target is $13.25
▲ +114.75% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for AngioDynamics in the last 3 months. The average price target is $13.25, with a high forecast of $17.00 and a low forecast of $10.00. The average price target represents a 114.75% upside from the last price of $6.17.

This chart shows the closing price for ANGO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in AngioDynamics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/21/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/21/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/19/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/17/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/16/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/15/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/14/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/13/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/22/2024HC WainwrightReiterated RatingBuy ➝ Buy$14.00Low
4/5/2024OppenheimerUpgradeMarket Perform ➝ Outperform$12.00Low
1/9/2024Raymond JamesLower TargetOutperform ➝ Outperform$12.00 ➝ $10.00Low
1/8/2024HC WainwrightLower TargetBuy ➝ Buy$20.00 ➝ $18.00Low
10/6/2023Raymond JamesLower TargetOutperform ➝ Outperform$13.00 ➝ $12.00Low
10/5/2023Canaccord Genuity GroupLower TargetBuy ➝ Buy$20.00 ➝ $17.00Low
10/5/2023HC WainwrightBoost TargetBuy ➝ Buy$19.00 ➝ $20.00Low
9/25/2023HC WainwrightInitiated CoverageBuy$19.00Low
7/13/2023Canaccord Genuity GroupBoost TargetBuy$18.00 ➝ $20.00Low
4/17/2023Raymond JamesDowngradeStrong-Buy ➝ Outperform$14.00 ➝ $13.00Low
4/3/2023Raymond JamesLower TargetStrong-Buy$22.00 ➝ $14.00Low
1/6/2023Raymond JamesLower TargetStrong-Buy$25.00 ➝ $22.00Low
10/7/2022Raymond JamesLower TargetStrong-Buy$27.00 ➝ $25.00Low
7/13/2022Canaccord Genuity GroupLower Target$40.00 ➝ $35.00Low
7/13/2022Raymond JamesLower TargetStrong-Buy$32.00 ➝ $27.00N/A
4/8/2022Canaccord Genuity GroupBoost Target$34.00 ➝ $40.00Medium
8/20/2021OppenheimerInitiated CoverageMarket PerformLow
7/9/2021Raymond JamesBoost TargetStrong-Buy$27.00 ➝ $32.00High
3/29/2021Raymond JamesReiterated RatingBuyLow
1/8/2021Raymond JamesBoost TargetStrong-Buy$18.00 ➝ $24.00High
11/26/2020Raymond JamesReiterated RatingHold ➝ NeutralLow
11/25/2020Raymond JamesUpgradeMarket Perform ➝ Strong-Buy$18.00High
10/4/2019KeyCorpLower TargetOverweight$30.00 ➝ $21.00High
(Data available from 6/13/2019 forward)

News Sentiment Rating

0.75 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
11/16/2023
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/16/2023
  • 4 very positive mentions
  • 13 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
1/15/2024
  • 7 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/14/2024
  • 7 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/15/2024
  • 8 very positive mentions
  • 15 positive mentions
  • 7 negative mentions
  • 0 very negative mentions
4/14/2024
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/14/2024
  • 6 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
6/13/2024

Current Sentiment

  • 6 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
AngioDynamics logo
AngioDynamics, Inc. provides invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology in the United States and internationally. It offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium for treatment of peripheral arterial disease. The company's thrombus management portfolio includes AlphaVac system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac circuit is indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. In addition, it offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. The company also provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.
Read More

Today's Range

Now: $6.17
Low: $6.12
High: $6.21

50 Day Range

MA: $6.24
Low: $5.78
High: $7.03

52 Week Range

Now: $6.17
Low: $5.26
High: $11.38

Volume

36,329 shs

Average Volume

518,437 shs

Market Capitalization

$247.17 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.68

Frequently Asked Questions

What sell-side analysts currently cover shares of AngioDynamics?

The following equities research analysts have issued reports on AngioDynamics in the last twelve months: Canaccord Genuity Group Inc., HC Wainwright, Oppenheimer Holdings Inc., Raymond James, and StockNews.com.
View the latest analyst ratings for ANGO.

What is the current price target for AngioDynamics?

4 Wall Street analysts have set twelve-month price targets for AngioDynamics in the last year. Their average twelve-month price target is $13.25, suggesting a possible upside of 114.7%. Canaccord Genuity Group Inc. has the highest price target set, predicting ANGO will reach $17.00 in the next twelve months. Raymond James has the lowest price target set, forecasting a price of $10.00 for AngioDynamics in the next year.
View the latest price targets for ANGO.

What is the current consensus analyst rating for AngioDynamics?

AngioDynamics currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ANGO will outperform the market and that investors should add to their positions of AngioDynamics.
View the latest ratings for ANGO.

What other companies compete with AngioDynamics?

Other companies that are similar to AngioDynamics include SeaSpine, Cytosorbents, Surmodics, Orthofix Medical and Accuray. Learn More about companies similar to AngioDynamics.

How do I contact AngioDynamics' investor relations team?

AngioDynamics' physical mailing address is 14 PLAZA DRIVE, LATHAM NY, 12110. The medical instruments supplier's listed phone number is (518) 795-1400 and its investor relations email address is [email protected]. The official website for AngioDynamics is www.angiodynamics.com. Learn More about contacing AngioDynamics investor relations.